NewAmsterdam Pharma Company N.V.
9.40%
10,578,806
1936258
N62509109
Aug 7, 2025
Aug 12, 2025, 04:30 PM
Reporting Persons (5)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| ForGrowth NAP B.V. | Other | 9.40% | 10,578,806 | 0 | 10,578,806 |
| Forbion Capital Fund IV Cooperatief U.A. | Other | 5.30% | 5,930,781 | 0 | 5,930,781 |
| Forbion IV Management B.V. | Other | 5.30% | 5,930,781 | 0 | 5,930,781 |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Other | 4.10% | 4,648,025 | 0 | 4,648,025 |
| Forbion Growth Management B.V. | Other | 4.10% | 4,648,025 | 0 | 4,648,025 |
Disclosure Items (2)
Ordinary Shares, Nominal value 0.12 per share
NewAmsterdam Pharma Company N.V.
Gooimeer 2-35, Naarden, P7, 1411 DC
(i) Forbion Growth I may be deemed to beneficially own 4,648,025 Ordinary Shares held through ForGrowth, representing approximately 4.1% of the outstanding Ordinary Shares, (ii) Forbion IV may be deemed to beneficially own 5,930,781 Ordinary Shares held through ForGrowth, representing approximately 5.3% of the of the outstanding Ordinary Shares and (iii) ForGrowth may be deemed to beneficially own 10,578,806 Ordinary Shares, representing approximately 9.4% of the outstanding Ordinary Shares, including an aggregate of 9,926,633 Ordinary Shares allocable to Forbion Growth I and Forbion IV through ForGrowth's interest in PoolCo. Forbion Growth Management may be deemed to beneficially own the Ordinary Shares that may be deemed to be beneficially owned by Forbion Growth I, and Forbion IV Management may be deemed to beneficially own the Ordinary Shares that may be deemed to be beneficially owned by Forbion IV. The percentage of the outstanding Ordinary Shares that may be deemed to be beneficially owned by the Reporting Persons is based upon 112,628,458 shares of the Issuer's Ordinary Shares outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on August 6, 2025.
See above.
Information concerning transactions in the Ordinary Shares of the Issuer effected since the most recent filing of Schedule 13D is set forth in Annex I of this Schedule 13D.
Not applicable.
Not applicable.